Sonoma Pharmaceuticals CEO, Stock, Wikipedia, News, Stock Price, Career And Board Of Directors.

0

Sonoma Pharmaceuticals

Sonoma Pharmaceuticals is a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, and dermatological conditions.

The company’s products reduce infections, itch, pain, scarring, and harmful inflammatory responses in a safe and effective manner. In-vitro and clinical studies of hypochlorous acid (HOCl) show it to have impressive antipruritic, antimicrobial, antiviral, and anti-inflammatory properties. Sonoma’s stabilized HOCl immediately relieves itch and pain, kills pathogens and breaks down biofilm, does not sting or irritate the skin, and oxygenates the cells in the area treated assisting the body in its natural healing process. The company’s products are sold either directly or via partners in 53 countries worldwide and the company actively seeks new distribution partners.

Recently, Sonoma announced that it had successfully closed an Asset Purchase Agreement with MicroSafe Group, for the exclusive rights of the Microcyn® technology-based disinfectant for sale in the Australian market under the brand name Nanocyn® and the European and Middle Eastern markets under the brand name MicroSafe®.

“We have been fighting global pandemics for nearly 20 years with our safe and non-toxic Microcyn® based disinfectant and we are very pleased with the test results and subsequent approval of the SARS-CoV-2 (COVID-19) label claim for our Nanocyn® disinfectant in Australia. The label claim comes with a 30 second virucidal kill time on hard surfaces, a landmark kills time for a non-toxic disinfectant,” Mrs. Safa Qadumi, Founder and CEO of the Microsoft Group Dubai, said.

“We have known for years that our Microcyn® Technology is effective against a number of pathogens, including viruses, so we are pleased to get this acknowledgment from the ARTG that our technology is effective in killing COVID-19,” said Amy Trombly, CEO of Sonoma Pharmaceuticals. She continued, “As the pandemic has spread around the world, we are excited to work with partners like MicroSafe Group to provide a safer environment for people during this difficult time. As an international company selling products in 53 countries around the world, we are continuously seeking additional partners to expand our domestic and global reach in distributing our products.”

Sonoma Pharmaceuticals Stock

Shares of Sonoma Pharmaceuticals Inc. SNOA, 231.24% nearly tripled on heavy volume in premarket trading Friday, after the California-based producer of hypochlorous acid products and partner Dubai-based MicroSafe Group said their Nanocyn disinfectant and sanitizer was entered into the Australian Register of Therapeutic Goods for use against the SARS-CoV-2 virus. Trading volume in Sonoma’s stock, which soared 160%, swelled to 1.6 million shares ahead of the open, compared with the full-day average of about 43,000 shares. Nanocyn is manufactured using Sonoma’s Microcyn technology.

“We have been fighting global pandemics for nearly 20 years with our safe and non-toxic Microcyn based disinfectant and we are very pleased with the test results and subsequent approval of the SARS-CoV-2 (COVID-19) label claim for our Nanocyn disinfectant in Australia,” said Microsoft Chief Executive Safa Qadumi. “The label claim comes with a 30 second virucidal kill time on hard surfaces, a landmark kills time for a non-toxic disinfectant.” Sonoma’s stock has gained 2.7% over the past three months through Thursday, while the S&P 500 SPX, -0.11% has tacked on 2.6%.

Sonoma Pharmaceuticals News

he company’s products reduce infections, itch, pain, scarring, and harmful inflammatory responses in a safe and effective manner. In-vitro and clinical studies of hypochlorous acid (HOCl) show it to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties. Sonoma’s stabilized HOCl immediately relieves itch and pain, kills pathogens and breaks down biofilm, does not sting or irritate skin and oxygenates the cells in the area treated assisting the body in its natural healing process. The company’s products are sold either directly or via partners in 53 countries worldwide and the company actively seeks new distribution partners.
Recently, Sonoma announced that it had successfully closed an Asset Purchase Agreement with MicroSafe Group, for the exclusive rights of the Microcyn® technology-based disinfectant for sale in the Australian market under the brand name Nanocyn® and the European and Middle Eastern markets under the brand name MicroSafe®.

“We have been fighting global pandemics for nearly 20 years with our safe and non-toxic Microcyn® based disinfectant and we are very pleased with the test results and subsequent approval of the SARS-CoV-2 (COVID-19) label claim for our Nanocyn® disinfectant in Australia. The label claim comes with a 30 second virucidal kill time on hard surfaces, a landmark kills time for a non-toxic disinfectant,” Mrs. Safa Qadumi, Founder and CEO of the Microsoft Group Dubai, said.

“We have known for years that our Microcyn® Technology is effective against a number of pathogens, including viruses, so we are pleased to get this acknowledgment from the ARTG that our technology is effective in killing COVID-19,” said Amy Trombly, CEO of Sonoma Pharmaceuticals. She continued, “As the pandemic has spread around the world, we are excited to work with partners like MicroSafe Group to provide a safer environment for people during this difficult time. As an international company selling products in 53 countries around the world, we are continuously seeking additional partners to expand our domestic and global reach in distributing our products.”

Sonoma Pharmaceuticals Stock

Shares of Sonoma Pharmaceuticals Inc. SNOA, 231.24% nearly tripled on heavy volume in premarket trading Friday, after the California-based producer of hypochlorous acid products and partner Dubai-based MicroSafe Group said their Nanocyn disinfectant and sanitizer was entered into the Australian Register of Therapeutic Goods for use against the SARS-CoV-2 virus. Trading volume in Sonoma’s stock, which soared 160%, swelled to 1.6 million shares ahead of the open, compared with the full-day average of about 43,000 shares. Nanocyn is manufactured using Sonoma’s Microcyn technology.

Sonoma Pharmaceuticals CEO

Amay Trombly is the CEO of Sonoma Pharmaceuticals

Sonoma Pharmaceuticals Wikipedia

As of May 2020, there is no written Wikipedia information about the company.

Sonoma Pharmaceuticals Investors

 

 

Leave A Reply

Your email address will not be published.